Posted by Michael Wonder on 31 May 2021
Schedule of Pharmaceutical Benefits - 1 June 2021
1 June 2021 - The June 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The June issue of the Schedule includes a few new/revised listings:
- Adalimumab (Humira) - new strength
- Beclomethasone dipropionate with eformoterol fumarate dihydrate and glycopyrronium bromide (Trimbow) - new combination product
- Bevacizumab (Mvasi) - new biosimilar medicine
- Galcanezumab (Emgality) - new medicine
- High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (KetoVie 3:1) - new formulation
- High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (KetoVie 4:1) - new formulation
- Progesterone (Oripro) - new indication
- Tenofovir disoproxil succinate with emtricitabine (Tenofovir/Emtricitabine Sandoz 301/200) - new formulation
- Tolvaptan (Jinarc) - new strength
Read Summary of PBS changes
Posted by:
Michael Wonder